Cellectis Statistics
Total Valuation
Cellectis has a market cap or net worth of $309.95 million. The enterprise value is $346.14 million.
Important Dates
The last earnings date was Friday, November 7, 2025, after market close.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Cellectis has 72.33 million shares outstanding. The number of shares has increased by 23.35% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 72.33M |
| Shares Change (YoY) | +23.35% |
| Shares Change (QoQ) | -40.44% |
| Owned by Insiders (%) | 2.20% |
| Owned by Institutions (%) | 7.26% |
| Float | 42.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.75 |
| Forward PS | 7.98 |
| PB Ratio | 3.08 |
| P/TBV Ratio | 3.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.19 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.49, with a Debt / Equity ratio of 0.88.
| Current Ratio | 1.49 |
| Quick Ratio | 0.53 |
| Debt / Equity | 0.88 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.31 |
Financial Efficiency
Return on equity (ROE) is -30.75% and return on invested capital (ROIC) is -8.08%.
| Return on Equity (ROE) | -30.75% |
| Return on Assets (ROA) | -4.47% |
| Return on Invested Capital (ROIC) | -8.08% |
| Return on Capital Employed (ROCE) | -13.58% |
| Revenue Per Employee | $371,851 |
| Profits Per Employee | -$159,248 |
| Employee Count | 222 |
| Asset Turnover | 0.22 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Cellectis has paid $514,000 in taxes.
| Income Tax | 514,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +121.39% in the last 52 weeks. The beta is 3.04, so Cellectis's price volatility has been higher than the market average.
| Beta (5Y) | 3.04 |
| 52-Week Price Change | +121.39% |
| 50-Day Moving Average | 3.53 |
| 200-Day Moving Average | 2.18 |
| Relative Strength Index (RSI) | 63.43 |
| Average Volume (20 Days) | 79,007 |
Short Selling Information
| Short Interest | 287,356 |
| Short Previous Month | 273,047 |
| Short % of Shares Out | 0.55% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.71 |
Income Statement
In the last 12 months, Cellectis had revenue of $82.55 million and -$35.35 million in losses. Loss per share was -$0.35.
| Revenue | 82.55M |
| Gross Profit | 82.55M |
| Operating Income | -26.41M |
| Pretax Income | -34.84M |
| Net Income | -35.35M |
| EBITDA | -13.87M |
| EBIT | -26.41M |
| Loss Per Share | -$0.35 |
Full Income StatementBalance Sheet
The company has $52.24 million in cash and $88.85 million in debt, giving a net cash position of -$36.61 million or -$0.51 per share.
| Cash & Cash Equivalents | 52.24M |
| Total Debt | 88.85M |
| Net Cash | -36.61M |
| Net Cash Per Share | -$0.51 |
| Equity (Book Value) | 100.48M |
| Book Value Per Share | 1.39 |
| Working Capital | 72.62M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$29.09 million and capital expenditures -$2.43 million, giving a free cash flow of -$31.52 million.
| Operating Cash Flow | -29.09M |
| Capital Expenditures | -2.43M |
| Free Cash Flow | -31.52M |
| FCF Per Share | -$0.44 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -31.99% and -42.83%.
| Gross Margin | 100.00% |
| Operating Margin | -31.99% |
| Pretax Margin | -42.20% |
| Profit Margin | -42.83% |
| EBITDA Margin | -16.81% |
| EBIT Margin | -31.99% |
| FCF Margin | n/a |
Dividends & Yields
Cellectis does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.35% |
| Shareholder Yield | -23.35% |
| Earnings Yield | -11.41% |
| FCF Yield | -10.17% |
Analyst Forecast
The average price target for Cellectis is $8.00, which is 94.41% higher than the current price. The consensus rating is "Buy".
| Price Target | $8.00 |
| Price Target Difference | 94.41% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 22.84% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cellectis has an Altman Z-Score of -0.68 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.68 |
| Piotroski F-Score | 3 |
